The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia

被引：23
|
作者：
Aumann, Shlomzion
Shaulov, Adir
Haran, Arnon
Even-Zohar, Noa Gross
Vainstein, Vladimir
Nachmias, Boaz [1 ]
机构：
[1] Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Hematol, IL-91120 Jerusalem, Israel
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2022年 / 23卷 / 18期
关键词：
venetoclax; acute lymphocytic leukemia; BCL-2; BCL-2; DEPENDENCE; IN-VITRO; CELL; SENSITIVITY; ABT-737; INHIBITION; AZACITIDINE; PATTERNS; EFFICACY; TARGETS;
D O I：
10.3390/ijms231810957
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Venetoclax, a B-cell lymphoma (BCL-2) inhibitor, in combination with hypomethylating agents has become the new standard of care in elderly and unfit patients with acute myeloid leukemia, with significantly improved overall survival and quality of life. Studies of venetoclax combined with high-dose chemotherapy are emerging with evidence of higher rates of molecular remission. Recently, a growing number of publications bring forth the use of venetoclax in patients with acute lymphoblastic leukemia (ALL). In the current review, we present the biological rationale of BCL-2 inhibition in ALL, how the interplay of BH3 proteins modulate the response and the current clinical experience with various combinations.
引用
收藏
页数：15
相关论文
共 50 条
  • [1] Venetoclax-based therapies for acute myeloid leukemia
    Guerra, Veronica A.
    DiNardo, Courtney
    Konopleva, Marina
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2019, 32 (02) : 145 - 153
  • [2] Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia
    Canaani, Jonathan
    Frisch, Avraham
    Pollyea, Daniel A.
    Schwartz, Marc
    Aumann, Shlomzion
    Ganzel, Chezi
    Haran, Arnon
    Even-Zohar, Noa Gross
    Shaulov, Adir
    Vainstein, Vladimir
    Moshe, Yakir
    Ofran, Yishai
    Wolach, Ofir
    Nachmias, Boaz
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (03) : 365 - 372
  • [3] Emerging Treatments in Acute Lymphoblastic Leukemia
    Crazzolara, R.
    Bendall, L.
    CURRENT CANCER DRUG TARGETS, 2009, 9 (01) : 19 - 31
  • [4] Venetoclax-Based Combination Regimens in Acute Myeloid Leukemia
    Goulart, Hannah
    Kantarjian, Hagop
    Pemmaraju, Naveen
    Daver, Naval
    Dinardo, Courtney D.
    Rausch, Caitlin R.
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD CANCER DISCOVERY, 2025, 6 (01): : 23 - 37
  • [5] Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia
    Molica, Stefano
    Allsup, David
    Gianfelici, Valentina
    Levato, Luciano
    Aiello, Vincenzo
    Bailey, James
    Polliack, Aaron
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (06) : 621 - 633
  • [6] Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia
    Oyogoa, Emmanuella
    Traer, Elie
    Tyner, Jeffrey
    Lachowiez, Curtis
    CANCERS, 2023, 15 (14)
  • [7] Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia
    Othman, Tamer A.
    Azenkot, Tali
    Moskoff, Benjamin N.
    Tenold, Matthew E.
    Jonas, Brian A.
    FUTURE ONCOLOGY, 2021, 17 (23) : 2989 - 3005
  • [8] Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies
    Griffioen, Mila S.
    de Leeuw, David C.
    Janssen, Jeroen J. W. M.
    Smit, Linda
    CANCERS, 2022, 14 (14)
  • [9] Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy
    Pei, Shanshan
    Pollyea, Daniel A.
    Gustafson, Annika
    Minhajuddin, Mohammad
    Stevens, Brett M.
    Ye, Haobin
    Inguva, Anagha
    Amaya, Maria L.
    Krug, Anna
    Jones, Courtney L.
    Adane, Biniam
    Winters, Amanda
    Khan, Nabilah
    Ponder, Jessica
    Schowinsky, Jeffrey
    Hammes, Andrew
    Abbott, Diana
    Myers, Jason R.
    Ashton, John M.
    Gutman, Jonathan A.
    Purev, Enkhtsetseg
    Ramsey, Haley E.
    Savona, Michael R.
    Fesik, Stephen W.
    Smith, Clayton
    Jordan, Craig T.
    BLOOD, 2019, 134
  • [10] Venetoclax-Based Regimen for Treatment of Patients with Acute Myeloid Leukemia in Community Based Practices
    Law, Lisa Y.
    Stevenson, Ryan
    Ho, Gwendolyn
    Nair, Bijay
    Laura, Asakura
    Sayegh, Antoine
    BLOOD, 2019, 134
12345